Over 80 Organizations Criticize Gilead for Price Hikes on HIV Medications

The AIDS Healthcare Foundation (AHF) has rallied over 80 organizations to express strong opposition to Gilead Sciences’ recent decision to implement high-single digit price increases on several of its HIV medications. In a letter sent on October 20, 2025, the coalition condemned Gilead’s strategy, asserting that these price hikes will severely impact the accessibility of essential treatments for low-income patients reliant on AIDS Drug Assistance Programs (ADAPs).

The price increases threaten to diminish the ability of ADAPs to provide vital prescriptions to those most in need. This program has been a critical support system for individuals living with HIV who lack sufficient financial resources. The organizations argue that the decision to raise prices is part of a troubling trend under the leadership of Gilead’s CEO, Daniel O’Day, which prioritizes profit over patient welfare.

In the letter, AHF and its partners highlighted the potential consequences of these price hikes. They warned that the increased costs would result in a significant reduction in the number of prescriptions available through ADAPs, ultimately leaving many patients without the medications necessary for their health and well-being.

The coalition’s actions reflect growing frustration with pharmaceutical companies that raise drug prices despite the ongoing public health crises. The letter serves as a call to action for Gilead to reconsider its pricing strategy and prioritize patient access to life-saving therapies.

AHF President Michael Weinstein stated, “It is unconscionable for Gilead to raise prices on medications that are already difficult for many patients to afford.” He stressed the importance of ensuring that all individuals have access to the treatment they need, regardless of their financial situation.

This letter comes at a time when healthcare costs continue to rise globally, and many organizations are advocating for more transparent pricing practices in the pharmaceutical industry. The AHF’s efforts to unite over 80 organizations against Gilead’s price increases highlight the collective discontent regarding drug affordability and the urgent need for reform in how medications are priced and distributed.

As the debate continues, the impact on patients remains a foremost concern. Without appropriate interventions, the price hikes could exacerbate health disparities and prevent vulnerable populations from receiving crucial medications to manage their conditions.

The AHF’s initiative underscores the power of collective advocacy in addressing healthcare inequities and the ongoing challenge of ensuring that life-saving treatments remain accessible for all, regardless of income.